Oct 7, 2019
qualitest.. 2016..
- b44iley
seen from Russia
seen from China
seen from Indonesia
seen from United States
seen from United States
seen from Germany
seen from United States
seen from Australia
seen from Japan
seen from Poland
seen from Argentina
seen from Germany
seen from China
seen from Algeria
seen from United States
seen from T1
seen from United States
seen from United States
seen from China
seen from United States
qualitest.. 2016..
- b44iley
qualitest 2016
- b44iley
qualitest and sprite in a fiji..2016..
- b44iley
Where it all started..
don't try and steal my photos..
faggot trend sippers..
-b44iley
hitch before akorn bought them out.. 2016..
- b44iley
The Associated Press: Communities across Appalachia band together for first-ever 13-state Narcan distribution event
An effort to destigmatize the use of overdose reversal drugs that started as a pilot in two West Virginia counties has expanded to all thirt
CHARLESTON, W.Va. (AP) — An effort to destigmatize the use of overdose reversal drugs that started as a pilot in two West Virginia counties has expanded to all thirteen states in Appalachia this year.
The first-ever “Appalachian Save a Life Day” comes Thursday, on the heels of the approval of Narcan as drug that can be purchased over the counter for nonprescription use — a long-awaited victory towards normalizing and improving access to the decades-old, live-saving medication.
More than 30,000 doses of naxolone, or Narcan, are being distributed in 13 states. Community organizations will then offer the drug for free at convenient locations like fast food restaurants, Walmarts, health departments, churches, convenience stores and fire departments.
More than 180 counties are participating at more than 300 different sites. The events are a celebration of what advocates have been working toward for years.
In 1971, the U.S. Food and Drug Administration approved use of naloxone, also referred to by its brand name “Narcan,” to treat overdoses. However, its use was confined to paramedics and hospitals. Narcan nasal spray was first approved by the FDA in 2015 as a prescription drug, and in March, it was approved for over-the-counter sales and started being available this month at major pharmacies for a suggested price of around $50 for two doses.
“It kind of gives you chills a little bit when you think about it, just because it’s this huge group of people coming together — and you don’t even know most of them — all because we deeply care about the same issue,” said Caroline Wilson, a social worker and person in recovery who organized Save a Life Day events in West Virginia’s Eastern Panhandle.
Spearheaded by the Charleston-based nonprofit Solutions-Oriented Drug Response, “Save a Life Day” began as a two-county pilot program in 2020 in West Virginia, expanding to 17 counties in-state in 2021. Last year, all 55 counties in the state with the nation’s highest rate of opioid overdoses in the nation participated. The 2023 event has expanded to include Alabama, Georgia, Kentucky, Maryland, Mississippi, New York, North Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, Virginia, and West Virginia.
The state of West Virginia dedicated $600,000 to this year’s effort. West Virginia’s Office of Drug Control Policy and the University of Charleston Pharmacy School have supplied naloxone for West Virginia’s events since its inception in 2020.
Solutions-Oriented Drug Response co-founder Sarah Stone said even in the last five years, she’s seen a major shift in the way people are talking about naloxone.
“I would say five years ago, people would easily say, ’Let people die, I would step over this person before I would offer assistance,’ or my personal favorite is: ’We can Narcan him three times, but not the fourth — there’s a limit,’” she said. “And you just don’t hear those things anymore, or not often.”
Braden Hopkins, a 20-year-old student at the University of Alabama, has been pushing for more naloxone and fentanyl test strip training and access within Greek life and other organizations. She’s invited medical professionals to her sorority for training and wants to see it normalized to the point where at least one person in every Greek life house is Narcan-trained.
Hopkins, who is vice president of the school’s chapter of Students for Sensible Drug Policy, said most of her peers don’t know what it is — a concerning thought at a school with a significant party culture, she said.
“People just don’t know how to have conversations about drugs and alcohol use,” said Hopkins, who will be tabling on the school’s quad distributing resources, test strips and doing HIV-testing outreach as part of Save a Life Day.
Harm Reduction Ohio, the largest distributor of naloxone in the state of Ohio, praised the greater availability of the drug but voiced concerns that the cost could prohibit those who need it most from getting it.
“I think over-the-counter is going to do a lot to decrease the stigma to when people see on a shelf, but $45 to $50, a dose is not going to help people who use drugs,” said AmandaLynn Reese, the organization’s chief program officer. “What we really need to do is make sure we are targeting the areas that need it.
Pharmacogenomics Market Worth $13.16 billion by 2029
Pharmacogenomics Market Worth $13.16 billion by 2029
According to this latest publication from Meticulous Research®, the global pharmacogenomics market is projected to reach $13.16 billion by 2029, at a CAGR of 8.6% during the forecast period 2022–2029. The growth of this market is driven by growing therapeutic applications of pharmacogenomics biomarkers, increasing adoption of personalized medicine, rising geriatric population and chronic disease prevalence, and growing awareness of adverse drug reactions. However, the high cost of personalized medicine and a lack of reimbursement for genetic testing & precision medicine restrain the market growth. The increasing application of pharmacogenomics in neurological disorders and cancer and the development of new, more advanced, and accurate diagnostic tools are creating growth opportunities for this market. However, the low awareness of pharmacogenomics/personalized medicine among people and the knowledge gap about genetic testing and its benefits pose a challenge to this market.
Pharmacogenomics Market: Future Outlook
The global pharmacogenomics market is segmented by technology (polymerase chain reaction, DNA sequencing, electrophoresis, microarray, mass spectrometry, and other technologies), application (oncology, cardiology, neurological diseases, infectious diseases, and other applications), end user (hospitals, diagnostic laboratories, academic and research institutions and other end users), and geography. The study also evaluates industry competitors and analyzes the market at regional and country levels.
Based on technology, in 2022, the polymerase chain reaction segment is expected to account for the largest share of the pharmacogenomics market. The large market share of this segment is attributed to the high availability and usage of PCR across all end users. PCR is a cost-effective alternative to NGS and other technologies. Moreover, PCR is a highly sensitive technology and provides results with high accuracy and low sample volume requirement. These benefits of PCR allow for its high adoption across all end users.
Based on application, in 2022, the oncology segment is expected to account for the largest share of the pharmacogenomics Market. The large market share of this segment is attributed to the need for more targeted approaches in cancer therapy, the benefits offered by pharmacogenomics in cancer treatment, and the prevalence of cancer worldwide. The high prevalence of cancer globally calls for early detection and targeted cancer therapy to reduce mortality due to cancer. According to the International Agency for Research on Cancer, the estimated global number of new cancer cases in 2020 was around 19.3 million.
Based on end user, in 2022, the hospitals segment is expected to account for the largest share of the Pharmacogenomics Market. Hospitals are the primary preference for diagnosing and treating any chronic or infectious disease. There is a rising trend among hospitals to equip themselves with molecular diagnostics tools. Moreover, the presence of certified medical practitioners in hospitals contributes to the higher adoption of pharmacogenomics testing. These factors further boost the growth of the pharmacogenomics market.
This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, and the Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa. Based on geography, in 2022, North America is expected to account for the largest share of the global pharmacogenomics market, followed by Europe and Asia-Pacific. The high prevalence of chronic diseases and high awareness regarding risks of diseases in the future, technological advancements in molecular and sequencing technologies, and highly developed healthcare infrastructure support the large market share of this region.
The key players operating in the global pharmacogenomics Market are F. Hoffmann-La Roche Ltd (Switzerland), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), OPKO Health, Inc. (U.S.), Dynamic DNA Laboratories (U.S.), Admera Health (U.S.), Qiagen N.V. (Netherlands), and Myriad Genetics, Inc. (U.S.).
𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗦𝗮𝗺𝗽𝗹𝗲 𝗥𝗲𝗽𝗼𝗿𝘁 @https://www.meticulousresearch.com/download-sample-report/cp_id=5366?utm_source=product&utm_medium=Social&utm_campaign=Product&utm_content=12-01-2023
Scope of the Report:
Pharmacogenomics Market, by Technology
Polymerase Chain Reaction
DNA Sequencing
Electrophoresis
Microarray
Mass Spectrometry
Other Technologies
(Note: Other Technologies include nucleic acid amplification technology, hybridization, and pyrosequencing)
Pharmacogenomics Market, by Application
Oncology
Cardiology
Neurologic Diseases
Infectious Diseases
Other Applications
(Note: Other Applications include pain management, psychiatry, forensic pathology, and basic research & drug development)
Pharmacogenomics Market, by End User
Hospitals
Diagnostic Laboratories
Academic & Research Institutions
Other End Users
(Other End Users include biopharmaceutical companies, clinical research organizations (CROS), and forensic laboratories)
Pharmacogenomics Market, by Geography
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe (RoE)
Asia-Pacific (APAC)
Japan
China
India
Rest of Asia-Pacific (RoAPAC)
Latin America
Brazil
Mexico
Rest of Latin America (RoLATAM)
Middle East & Africa
Plasma donation companies: drawing the blood of the working poor for profit
Plasma donation companies: drawing the blood of the working poor for profit
There’s a jittery and anxious energy to the air. The music is alternating between high-energy jazz and Christmas carols belted over the intercom. A groundswell of regular plasma donors are jostling between black rope lines, hastily filling out informed consent forms at one of the many self-check-in kiosks, or slumped over on the dark plastic chairs that line the waiting room from…
View On WordPress